These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 16206354)

  • 61. Cost-effectiveness of oral ibandronate versus IV zoledronic acid or IV pamidronate for bone metastases in patients receiving oral hormonal therapy for breast cancer in the United Kingdom.
    De Cock E; Hutton J; Canney P; Body JJ; Barrett-Lee P; Neary MP; Lewis G
    Clin Ther; 2005 Aug; 27(8):1295-310. PubMed ID: 16199254
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Comparison of the efficacy between once-monthly oral ibandronate and risedronate among Korean women with osteoporosis: a nationwide population-based study.
    Lee DR; Lee J
    Osteoporos Int; 2019 Mar; 30(3):659-666. PubMed ID: 30535785
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Efficacy and safety of oral weekly ibandronate in the treatment of postmenopausal osteoporosis.
    Cooper C; Emkey RD; McDonald RH; Hawker G; Bianchi G; Wilson K; Schimmer RC
    J Clin Endocrinol Metab; 2003 Oct; 88(10):4609-15. PubMed ID: 14557430
    [TBL] [Abstract][Full Text] [Related]  

  • 64. [Therapeutic agents for disorders of bone and calcium metabolism: Ibandronate].
    Hashimoto J
    Clin Calcium; 2007 Jan; 17(1):11-7. PubMed ID: 17211088
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: results of a meta-analysis of phase III studies.
    Harris ST; Blumentals WA; Miller PD
    Curr Med Res Opin; 2008 Jan; 24(1):237-45. PubMed ID: 18047776
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group.
    Schnitzer T; Bone HG; Crepaldi G; Adami S; McClung M; Kiel D; Felsenberg D; Recker RR; Tonino RP; Roux C; Pinchera A; Foldes AJ; Greenspan SL; Levine MA; Emkey R; Santora AC; Kaur A; Thompson DE; Yates J; Orloff JJ
    Aging (Milano); 2000 Feb; 12(1):1-12. PubMed ID: 10746426
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Monthly ibandronate suppresses serum CTX-I within 3 days and maintains a monthly fluctuating pattern of suppression.
    Binkley N; Silverman SL; Simonelli C; Santiago N; Kohles JD; Dasic G; Sunyecz JA
    Osteoporos Int; 2009 Sep; 20(9):1595-601. PubMed ID: 19145396
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Oral ibandronate: a less frequently administered therapeutic option for postmenopausal osteoporosis.
    Reginster JY
    Expert Opin Pharmacother; 2005 Oct; 6(13):2301-13. PubMed ID: 16218890
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Optimizing dosing frequencies for bisphosphonates in the management of postmenopausal osteoporosis: patient considerations.
    Sunyecz J
    Clin Interv Aging; 2008; 3(4):611-27. PubMed ID: 19281054
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Question: In postmenopausal women with osteoporosis is once monthly oral ibandronate (150 mg) therapy preferred to once weekly oral bisphosphonate therapy.
    Dave M; Criswell DF
    J Okla State Med Assoc; 2012 Mar; 105(3):89-90. PubMed ID: 22685920
    [No Abstract]   [Full Text] [Related]  

  • 71. A semimechanistic and mechanistic population PK-PD model for biomarker response to ibandronate, a new bisphosphonate for the treatment of osteoporosis.
    Pillai G; Gieschke R; Goggin T; Jacqmin P; Schimmer RC; Steimer JL
    Br J Clin Pharmacol; 2004 Dec; 58(6):618-31. PubMed ID: 15563360
    [TBL] [Abstract][Full Text] [Related]  

  • 72. [The benefit from ibandronate in the treatment of postmenopausal osteoporosis].
    Málek Z
    Vnitr Lek; 2007 Oct; 53(10):1114-8. PubMed ID: 18072438
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva Alendronate Trial in Osteoporosis (BALTO).
    Emkey R; Koltun W; Beusterien K; Seidman L; Kivitz A; Devas V; Masanauskaite D
    Curr Med Res Opin; 2005 Dec; 21(12):1895-903. PubMed ID: 16368038
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Prospective clinical study of once monthly ibandronate in the treatment of osteoporosis and prevention of fractures in postmenopausal women: ORPHEUM Study.
    Bumbasirević M; Lesić A; Denić-Marković L; Zivković K;
    Srp Arh Celok Lek; 2011; 139(11-12):790-4. PubMed ID: 22338477
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Treatment preference for monthly oral ibandronate and weekly oral alendronate in women with postmenopausal osteoporosis: A randomized, crossover study (BALTO II).
    Hadji P; Minne H; Pfeifer M; Bourgeois P; Fardellone P; Licata A; Devas V; Masanauskaite D; Barrett-Connor E
    Joint Bone Spine; 2008 May; 75(3):303-10. PubMed ID: 18069036
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Upper gastrointestinal tract safety profile of alendronate: the fracture intervention trial.
    Bauer DC; Black D; Ensrud K; Thompson D; Hochberg M; Nevitt M; Musliner T; Freedholm D
    Arch Intern Med; 2000 Feb; 160(4):517-25. PubMed ID: 10695692
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Ibandronate: a potent new bisphosphonate in the management of postmenopausal osteoporosis.
    Papapoulos SE
    Int J Clin Pract; 2003 Jun; 57(5):417-22. PubMed ID: 12846348
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Effects of intermittent intravenous ibandronate injections on bone quality and micro-architecture in women with postmenopausal osteoporosis: the DIVA study.
    Recker RR; Ste-Marie LG; Langdahl B; Czerwinski E; Bonvoisin B; Masanauskaite D; Rowell L; Felsenberg D
    Bone; 2010 Mar; 46(3):660-5. PubMed ID: 19909829
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Preventing nonvertebral osteoporotic fractures with extended-interval bisphosphonates: regimen selection and clinical application.
    Cole RE; Harris ST
    Medscape J Med; 2009; 11(1):12. PubMed ID: 19295933
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Effects of intravenous ibandronate injection on renal function in women with postmenopausal osteoporosis at high risk for renal disease--the DIVINE study.
    Miller PD; Ragi-Eis S; Mautalen C; Ramirez F; Jonkanski I
    Bone; 2011 Dec; 49(6):1317-22. PubMed ID: 21945737
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.